New Fibroid Management Guidance from the American College of Obstetricians & Gynecologists Supports Laparoscopic Radiofrequen...
May 24 2021 - 08:24AM
Business Wire
--Hologic’s Acessa®
Procedure Now Part of the Procedural Intervention Standard of Care
for Uterine Fibroids--
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health,
announced today that the American College of Obstetricians and
Gynecologists (ACOG), in its updated guidance for Management of
Symptomatic Uterine Leiomyomas, supports the use of laparoscopic
radiofrequency ablation (Lap-RFA) for the treatment of uterine
fibroids.
The inclusion of Lap-RFA in ACOG’s updated guidance means that
Hologic’s Acessa® procedure can be considered as a minimally
invasive, uterine preserving option for patients with symptomatic
leiomyomas who are counseled about the limited data on reproductive
outcomes.1 While Lap-RFA can be a safe and effective treatment
option for many women, ACOG’s guidance acknowledges that access to
RFA technology remains limited.1 ACOG’s recognition of Lap-RFA
treatment as an alternative to hysterectomy or myomectomy is an
important step toward expanding access to this important
evidence-based minimally invasive option.
“This is a significant milestone for the millions of women who
suffer from uterine fibroids, and for the physicians who treat
them,” says Essex Mitchell, Division President, GYN Surgical
Solutions, Hologic. “By supporting the use of Lap-RFA in its
updated guidance, ACOG will inspire physicians to offer more
options, like the Acessa procedure, that bridge the gap between
medical management and major surgery for uterine fibroids.”
“Treating a benign condition such as uterine fibroids with full
removal of the uterus through hysterectomy is not necessary for
most patients, especially with less invasive options readily
available,” says Dr. Soyini Hawkins, MD, MPH, FACOG. “Within my own
practice, the Acessa procedure has been a valuable option to not
only improve outcomes but also quality of life for women living
with uterine fibroids. ACOG’s updated guidance in Practice Bulletin
Number 228 will help physicians and patients considering fibroid
treatment recognize Lap-RFA as a safe and effective uterine sparing
option.”
The Acessa procedure provides a minimally invasive,
uterine-sparing surgical option for women with symptomatic fibroids
who would otherwise require more invasive intervention. Acessa
Lap-RFA involves a simple three-step approach: visualize, deploy,
and treat. This treatment combines laparoscopic ultrasound with
radiofrequency ablation to destroy fibroid tissue through
coagulation necrosis. It does not require laparoscopic suturing and
patients typically go home on NSAIDs.2 By approaching fibroids
laparoscopically, physicians benefit from a full view of the pelvic
anatomy throughout the procedure.
About Hologic, Inc. Hologic, Inc. is an innovative
medical technology company primarily focused on improving women's
health and well-being through early detection and treatment. For
more information on Hologic, visit www.hologic.com.
Forward-Looking
Statements
This press release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic’s products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient. The actual effect of the use of the products
can only be determined on a case-by-case basis depending on the
particular circumstances and patient in question. In addition,
there can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such statements
are based.
Hologic, Acessa, Acessa ProVu, MyoSure, and The Science of Sure
are trademarks and/or registered trademarks of Hologic, Inc. and/or
its subsidiaries in the United States and/or other countries.
References 1 American College of Obstetricians and
Gynecologists. (2021). Practice Bulletin Number 228. Management of
Symptomatic Uterine Leiomyomas. Access here:
https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2021/06/management-of-symptomatic-uterine-leiomyomas
2 SG Chudnoff, et al. Outpatient Procedure for the Treatment and
Relief of Symptomatic Uterine Myomas. Obstetrics and Gynecology,
2013;121(5):1075-82.
SOURCE: Hologic, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210524005456/en/
Jane Mazur (508) 263-8764 (direct) (585) 355-5978 (mobile)
Jane.Mazur@hologic.com Michael Watts (858) 410-8588
Michael.Watts@hologic.com
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Mar 2023 to Mar 2024